HZN-825
Idiopathic Pulmonary Fibrosis
Clinical trials
1
Developer
Amgen
Overview
HZN-825 is an agent tracked by PF-Atlas in the context of idiopathic pulmonary fibrosis. It appears in 1 tracked IPF clinical trial.
HZN-825 clinical trials
Explore related
Medical disclaimer. This page summarizes research about HZN-825 for information only. It is not medical advice. Verify approval status and evidence with the FDA and a pulmonologist.